[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1070881A1 - Novel delta-amino-gamma-hydroxy-ometa-aryl-alkanoic acid amides - Google Patents

Novel delta-amino-gamma-hydroxy-ometa-aryl-alkanoic acid amides

Info

Publication number
HK1070881A1
HK1070881A1 HK05103691A HK05103691A HK1070881A1 HK 1070881 A1 HK1070881 A1 HK 1070881A1 HK 05103691 A HK05103691 A HK 05103691A HK 05103691 A HK05103691 A HK 05103691A HK 1070881 A1 HK1070881 A1 HK 1070881A1
Authority
HK
Hong Kong
Prior art keywords
opt
substd
alkylene
cooh
mono
Prior art date
Application number
HK05103691A
Other languages
English (en)
Inventor
Richard Goeschke
Juergen Klaus Maibaum
Walter Schilling
Stefan Stutz
Pascal Rigollier
Yasuchika Yamaguchi
Nissim Claude Cohen
Peter Herold
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4204102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1070881(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1070881A1 publication Critical patent/HK1070881A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/11—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton
    • C07C255/13—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK05103691A 1994-04-18 2005-04-29 Novel delta-amino-gamma-hydroxy-ometa-aryl-alkanoic acid amides HK1070881A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH116994 1994-04-18

Publications (1)

Publication Number Publication Date
HK1070881A1 true HK1070881A1 (en) 2005-06-30

Family

ID=4204102

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05103691A HK1070881A1 (en) 1994-04-18 2005-04-29 Novel delta-amino-gamma-hydroxy-ometa-aryl-alkanoic acid amides

Country Status (27)

Country Link
US (5) US5559111A (el)
EP (1) EP0678503B1 (el)
JP (1) JP3240322B2 (el)
KR (1) KR100353779B1 (el)
CN (2) CN1153759C (el)
AT (1) ATE183997T1 (el)
AU (1) AU699616B2 (el)
BR (1) BR1100656A (el)
CA (1) CA2147056C (el)
CY (4) CY2208B1 (el)
CZ (1) CZ287935B6 (el)
DE (4) DE122009000020I1 (el)
DK (1) DK0678503T3 (el)
ES (1) ES2137478T3 (el)
FI (1) FI118336B (el)
GR (1) GR3031997T3 (el)
HK (1) HK1070881A1 (el)
HU (2) HU226860B1 (el)
IL (1) IL113403A (el)
LU (2) LU91373I2 (el)
MY (1) MY119161A (el)
NL (2) NL300296I2 (el)
NO (4) NO310410B1 (el)
NZ (1) NZ270936A (el)
RU (1) RU95105970A (el)
TW (2) TW366341B (el)
ZA (3) ZA953051B (el)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4408534A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Substituierte N-Ethyl-Glycinderivate zur Herstellung von PNA und PNA-/DNA-Hybriden
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0716077A1 (de) * 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
US6465650B1 (en) 1995-03-13 2002-10-15 Aventis Pharma Deutschland Gmbh Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids
DK1045839T3 (da) * 1997-12-16 2004-07-05 Warner Lambert Co Hidtil ukendte aminer som farmaceutiske midler
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) * 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6423850B1 (en) 1999-06-18 2002-07-23 E.I. Du Pont De Nemours And Company Preparation and use of gamma-butyrolactones as cross-linking agents
US6833460B2 (en) * 1999-06-18 2004-12-21 E. I. Du Pont De Nemours And Company Preparation and use of gamma-butyrolactones as cross-linking agents
US7009078B1 (en) * 1999-07-29 2006-03-07 Speedel Pharma Ag Production of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-arly-octanoylamides
CN1293026C (zh) * 2000-07-03 2007-01-03 斯皮德尔药品公司 制备(r)－2－烷基－3－苯基－1－丙醇的方法
PT1296935E (pt) 2000-07-05 2009-05-15 Novartis Ag Processo para a preparação de octanoil amidas substituídas
DE122007000077I2 (de) * 2000-07-25 2008-08-21 Speedel Pharma Ag Hirchgaessle Verfahren zur herstellung von substituierten octanoyl-amiden
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
PT1215201E (pt) * 2000-12-14 2007-02-28 Speedel Pharma Ag Processo para a preparação de ariloctanoil amidas
JP3440082B2 (ja) 2001-02-19 2003-08-25 科学技術振興事業団 電気自動車用インホイールモーター
DE60235374D1 (de) 2001-05-15 2010-04-01 Novartis Ag Verfahren zur herstellung von substituierten carbonsäureestern mittels enzymatischer hydrolyse
MXPA03011502A (es) * 2001-06-11 2004-03-26 Upjohn Co Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.
BR0213357A (pt) * 2001-10-18 2004-10-26 Novartis Ag Compostos orgânicos
US20050101638A1 (en) * 2002-11-08 2005-05-12 Webb Randy L. Combination of organic compounds
SI1507558T1 (sl) * 2002-05-17 2011-12-30 Novartis Pharma Ag Farmacevtski sestavek, ki obsega reninski inhibitor, blokator kalcijevega kanala in diuretik
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
AU2003238007A1 (en) * 2002-06-11 2003-12-22 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
US20060089355A1 (en) * 2002-06-11 2006-04-27 Michel Maillard Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides
US7470709B2 (en) * 2002-08-23 2008-12-30 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US7049469B2 (en) 2002-10-24 2006-05-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing (R)-salbutamol
MXPA05005649A (es) 2002-11-27 2005-08-16 Elan Pharm Inc Ureas y carbamatos sustituidos.
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
CA2536480A1 (en) * 2003-08-25 2005-03-03 Warner-Lambert Company Llc Novel antimicrobial aryloxazolidinone compounds
EP1689702B1 (en) * 2003-11-26 2013-01-30 Novartis AG Organic compounds
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
PE20050596A1 (es) * 2003-12-19 2005-10-18 Novartis Ag Microemulsion que comprende un inhibidor renina
RU2006130005A (ru) * 2004-01-22 2008-02-27 Новартис АГ (CH) Комбинация органических соединений
ES2348016T3 (es) * 2004-01-23 2010-11-26 Novartis Ag Diamino alcoholoes y su uso como inhibidores de la renina.
ES2357585T3 (es) * 2004-01-23 2011-04-27 Novartis Ag Derivados de aminoalcoholes y su actividad como inhibidores de la renina.
US20070191487A1 (en) * 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
RU2426532C2 (ru) 2004-03-17 2011-08-20 Новартис Аг Применение органических соединений
AR048431A1 (es) * 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
DE602005012481D1 (de) * 2004-03-19 2009-03-12 Speedel Experimenta Ag 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
JP4927704B2 (ja) * 2004-03-19 2012-05-09 シュペーデル・エクスペリメンタ・アーゲー 有機化合物
WO2005095876A1 (en) 2004-04-01 2005-10-13 Cucumber Limited Delivery and storage of goods
GB0419361D0 (en) 2004-08-31 2004-10-06 Novartis Ag Organic compounds
JP2008515903A (ja) 2004-10-08 2008-05-15 ノバルティス アクチエンゲゼルシャフト 拡張機能障害または拡張期心不全の予防または処置のためのレニン阻害剤の使用
TW200633983A (en) * 2004-12-10 2006-10-01 Speedel Experimenta Ag 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-nonanamides
TW200631929A (en) * 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
US20080293701A1 (en) * 2005-02-02 2008-11-27 Baldwin John J 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors
CN101171230A (zh) * 2005-03-11 2008-04-30 斯皮德尔实验股份公司 用作肾素抑制剂的杂环取代的链烷酰胺
TW200700358A (en) * 2005-03-11 2007-01-01 Speedel Experimenta Ag Organic compounds
PL1861352T3 (pl) * 2005-03-17 2010-05-31 Basf Se Sposób wytwarzania optycznie czynnych pochodnych kwasu 3-fenylopropionowego i otrzymywane z nich produkty
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
WO2007006532A1 (en) 2005-07-11 2007-01-18 Novartis Ag New pyrocatechin derivatives
US20070021413A1 (en) 2005-07-20 2007-01-25 Peter Herold Diamino alcohols as therapeutic compounds
WO2007009250A1 (en) * 2005-07-22 2007-01-25 Merck Frosst Canada Ltd. Renin inhibitors
EP1764098A1 (en) * 2005-09-17 2007-03-21 Speedel Experimenta AG Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV
ES2328630T3 (es) 2005-09-17 2009-11-16 Novartis Ag Derivados de 5-amino-4-hydroxi-7-(imidazo (1,2-a>)piridin-6- ilmetil-8-metil-nonamida y compuestos relacionados como inhibidores de la renina para el tratamiento de la hipertension.
BRPI0616219A2 (pt) * 2005-09-17 2011-06-14 Speedel Experimenta Ag amidas de Ácidos alcanàicos substituÍdas por o-heterociclos saturados
GB0519764D0 (en) * 2005-09-28 2005-11-09 Novartis Ag Organic compounds
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
EP1934186A2 (en) * 2005-10-18 2008-06-25 NicOx S.A. Renin inhibitors nitroderivatives
KR20080059233A (ko) 2005-10-21 2008-06-26 노파르티스 아게 레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물
GB2431642A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431646A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431648A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431649A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431645A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
DE102005052195A1 (de) 2005-10-28 2007-05-03 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von chiralen Octensäurederivaten
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
GB0605688D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic compounds
WO2007120523A2 (en) * 2006-03-31 2007-10-25 Vitae Pharmaceuticals, Inc. 6-(aminoalkyl)indazoles
WO2007123718A1 (en) * 2006-03-31 2007-11-01 Vitae Pharmaceuticals, Inc. 1-HETEROCYCLYLAMINO-2-HYDROXY-3-AMINO-ω-ARYLALKANES
SG170830A1 (en) * 2006-04-03 2011-05-30 Novartis Ag Renin inhibitors for the treatment of hypertension
WO2007148775A1 (ja) * 2006-06-23 2007-12-27 Daiichi Sankyo Company, Limited 鎖状アミン化合物
KR20090031517A (ko) * 2006-06-23 2009-03-26 다이이찌 산쿄 가부시키가이샤 고리형 아민 화합물
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
JP5042311B2 (ja) 2006-07-20 2012-10-03 ノバルティス アーゲー Ｃｅｔｐ阻害剤としてのアミノピペリジン誘導体
EP1911762A1 (en) 2006-10-04 2008-04-16 Speedel Experimenta AG Amino alcohols and their use as renin inhibitors
CN101594857B (zh) * 2006-11-07 2012-10-31 诺瓦提斯公司 阿利吉仑半富马酸盐的晶形
EP2089356B1 (en) * 2006-11-09 2012-04-25 Novartis AG Salt of aliskiren with orotic acid
EP1938812A1 (en) * 2006-12-22 2008-07-02 Speedel Pharma AG Pharmaceutical composition using aliskiren and avosentan
EP1958666A1 (en) 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
WO2008113835A1 (en) * 2007-03-21 2008-09-25 Novartis Ag Process for preparing (r or s)-5-{1-azido-3-[6-methoxy-5-(3-methoxy-propoxy)-pyridin-3-ylmethyl]-4-methyl-pentyl}-3-alkyl-dihydro-furan-2-one
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
CA2681203A1 (en) * 2007-04-03 2008-10-09 Novartis Ag New methods
CN101801903A (zh) * 2007-07-11 2010-08-11 帝斯曼知识产权资产管理有限公司 饱和醛的制备
US20090076062A1 (en) * 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
US20090082458A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched aliskiren
MY148266A (en) 2007-09-28 2013-03-29 Novartis Ag Galenical formulations of aliskiren
DE102007049039A1 (de) 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
EP2463282B1 (en) 2007-11-05 2013-08-07 Novartis AG 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
JP2011503185A (ja) 2007-11-13 2011-01-27 テバ ファーマシューティカル インダストリーズ リミティド ヘミフマル酸アリスキレンの多形形態及びその調製プロセス
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
WO2009071509A1 (en) 2007-12-03 2009-06-11 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
EP2075244A1 (en) 2007-12-24 2009-07-01 DSMIP Assets B.V. New route to building block for making renin inhibitors
WO2009104939A2 (ko) 2008-02-22 2009-08-27 한올제약주식회사 약제학적 제제
EP2275093A2 (en) 2008-04-10 2011-01-19 HanAll Biopharma Co., Ltd. Pharmaceutical formulation
CA2724746A1 (en) * 2008-05-23 2009-11-26 Teva Pharmaceuticals Industries Ltd. Aliskiren monofumarate and processes for preparation thereof
US20120095264A1 (en) * 2008-06-06 2012-04-19 Teva Pharmaceutical Industries Ltd. Solid states of aliskiren free base
EP2143425A1 (de) 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
EP2163245A1 (en) 2008-09-10 2010-03-17 Novartis Ag Renin inhibitors for the treatment of psoriasis
EP2189442B1 (en) 2008-11-20 2014-10-01 Krka Tovarna Zdravil, D.D., Novo Mesto Process and intermediates for the preparation of aliskiren
RU2535090C2 (ru) 2009-01-28 2014-12-10 Новартис Аг Галеновы препараты органических соединений
EP2273990A2 (en) 2009-02-05 2011-01-19 Teva Pharmaceutical Industries Ltd. Solid state forms of aliskiren compounds
EA201190091A1 (ru) 2009-02-05 2012-01-30 Крка, Товарна Здравил, Д. Д., Ново Место Активируемый влагой способ грануляции
AU2010226620A1 (en) 2009-03-20 2011-09-22 Novartis Ag Galenical formulations of a fixed dose combination of Valsartan and Aliskiren
AU2010226615A1 (en) 2009-03-20 2011-09-15 Novartis Ag Pharmaceutical composition comprising Aliskiren
US20120149895A1 (en) 2009-04-01 2012-06-14 Lek Pharmaceuticals D.D. Process for dimethylation of active methylene groups
JP5746696B2 (ja) * 2009-08-11 2015-07-08 ノバルティス アーゲー ラクトンおよびラクタムの開環
US20120220663A1 (en) 2009-09-03 2012-08-30 Teva Pharmaceuticals Usa, Inc. Solid forms of aliskiren hemifumarate and processes for preparation thereof
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
WO2011048523A1 (en) * 2009-10-21 2011-04-28 CarboDesign LLC Process for the manufacture of enantiomerically pure aryloctanoic acids as aliskiren
WO2011051853A1 (en) * 2009-10-29 2011-05-05 CarboDesign LLC Manufacturing process for preparing enaniomerically pure 8- aryloctanoic acid derivatives such as aliskiren
KR20120130078A (ko) * 2009-11-09 2012-11-28 메디비르 아베 신규한 1,3-옥사졸리딘 화합물 및 이의 레닌 억제제로서의 용도
US20110113995A1 (en) * 2009-11-13 2011-05-19 Lindsay Corporation Method and apparatus for planting and irrigation
US20110137047A1 (en) * 2009-12-07 2011-06-09 CarboDesign LLC Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
CN101774986B (zh) 2010-01-06 2012-03-28 浙江天宇药业股份有限公司 一种制备阿利克伦及其中间体的方法
CN102140068B (zh) * 2010-01-30 2015-03-11 浙江华海药业股份有限公司 阿利吉仑中间体3-氨基-2,2-二甲基丙酰胺的制备方法
EP2523934A1 (en) * 2010-02-10 2012-11-21 Ratiopharm GmbH Salts of aliskiren
AR080683A1 (es) 2010-03-16 2012-05-02 Novartis Ag Composiciones farmaceuticas de aliskiren y metodos de administracion
TR201002256A1 (tr) * 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
EP2382967A1 (de) 2010-04-21 2011-11-02 ratiopharm GmbH Aliskiren in Form einer festen Dispersion
US20110268797A1 (en) 2010-04-30 2011-11-03 Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi Multicoated aliskiren formulations
CN102241650B (zh) * 2010-05-14 2014-05-07 浙江九洲药业股份有限公司 用于制备阿立克仑的中间体化合物及相关制备方法
IT1400961B1 (it) * 2010-06-04 2013-07-05 Chemo Iberica Sa Processo per la produzione di aliskiren
TW201202178A (en) 2010-06-04 2012-01-16 Chemo Iberica Sa Process for producing Aliskiren
IT1402925B1 (it) * 2010-12-10 2013-09-27 Chemo Iberica Sa Processo per la produzione di aliskiren
CN101913998A (zh) * 2010-07-06 2010-12-15 上海朴颐化学科技有限公司 4-溴-2-(3-甲氧基丙氧基)-苯甲醚的制备方法
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
PT2630118E (pt) 2010-10-19 2015-02-10 Mylan Lab Ltd Síntese do aliskiren
CN102001920B (zh) 2010-11-09 2013-05-15 常州制药厂有限公司 一种药物中间体的制备方法
CN102161627A (zh) * 2011-02-24 2011-08-24 中国药科大学 ω-(N取代-氨基烷基)辛酰胺
EP2551260A1 (en) 2011-07-28 2013-01-30 Chemo Ibérica, S.A. Chemical process for opening ring compounds
CN102942477B (zh) * 2011-08-14 2015-12-02 浙江华海药业股份有限公司 辛烯酸衍生物及其制备方法
CN102351734B (zh) * 2011-09-05 2014-02-26 浙江普洛医药科技有限公司 一种阿利克仑的制备方法
WO2013045505A1 (en) 2011-09-28 2013-04-04 Novartis Ag Biomarkers for raas combination therapy
US8703976B2 (en) * 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
WO2013061224A1 (en) 2011-10-25 2013-05-02 Jubilant Life Sciences Limited Process for the preparation of aliskiren
WO2013118138A1 (en) 2011-12-13 2013-08-15 Laboratories Ltd Mylan Novel process for the preparation of renin inhibitors
CN103172533B (zh) * 2011-12-20 2016-05-04 博瑞生物医药（苏州）股份有限公司 一种阿利克仑半富马酸盐的新晶型及其制备方法和用途
CN103204834A (zh) * 2012-01-11 2013-07-17 南京欧信医药技术有限公司 阿利克伦中间体及其制备方法和应用
EP2814806B1 (en) 2012-02-17 2016-05-25 Mylan Laboratories Ltd. An improved process for the preparation of aliskiren
WO2013124868A2 (en) 2012-02-21 2013-08-29 Mylan Laboratories Limited Solid form of aliskiren intermediate
ITMI20120354A1 (it) * 2012-03-07 2013-09-08 Friulchem Spa Processo per la produzione di aliskirene
WO2013144979A1 (en) 2012-03-28 2013-10-03 Maylan Laboratories Ltd Process for the preparation of aliskiren
CN104284847A (zh) 2012-05-11 2015-01-14 诺华股份有限公司 分配装置
WO2013171767A1 (en) 2012-05-18 2013-11-21 Mylan Laboratories Limited An improved process for the preparation of aliskiren
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
US9550797B2 (en) * 2013-06-27 2017-01-24 Patheon Holdings I B.V. Preparation of Grignard reagents using a fluidized bed
CA3103599A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
CN112679448B (zh) * 2020-12-31 2022-08-19 苏州昊帆生物股份有限公司 N-(2-氨基乙基)吗啉的制备方法
CN115340472B (zh) * 2022-09-19 2024-05-07 合肥工业大学 一种谷氨酸衍生物及其合成方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337207A (en) * 1980-09-04 1982-06-29 Regents Of The University Of California Biologically active catecholamine derivatives
US4729985A (en) * 1985-08-09 1988-03-08 Pfizer Inc. Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
JPH02124884A (ja) * 1988-07-08 1990-05-14 Zhongguo Yixuekexueyuan Yaowo Yanjiusuo Ｎ―置換アミド誘導体
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities

Also Published As

Publication number Publication date
DE122011100052I1 (de) 2012-01-19
NO2009011I2 (no) 2010-11-22
CN1153759C (zh) 2004-06-16
NO2007011I2 (el) 2011-07-25
CY2208B1 (en) 2002-11-08
NO2007011I1 (no) 2007-12-11
US5646143A (en) 1997-07-08
HUT71701A (en) 1996-01-29
ZA953050B (en) 1995-11-08
AU1642195A (en) 1995-10-26
US5654445A (en) 1997-08-05
US5705658A (en) 1998-01-06
HU9501076D0 (en) 1995-06-28
CN1117960A (zh) 1996-03-06
ATE183997T1 (de) 1999-09-15
NL300386I1 (nl) 2009-07-01
AU699616B2 (en) 1998-12-10
EP0678503B1 (de) 1999-09-01
RU95105970A (ru) 1997-01-10
CZ97695A3 (en) 1995-11-15
GR3031997T3 (en) 2000-03-31
CY2009006I2 (el) 2010-07-28
CY2011015I1 (el) 2014-04-09
FI951771A0 (fi) 1995-04-12
KR950032037A (ko) 1995-12-20
EP0678503A1 (de) 1995-10-25
TW366341B (en) 1999-08-11
JPH0881430A (ja) 1996-03-26
BR1100656A (pt) 2000-06-06
DK0678503T3 (da) 2000-03-20
NO951441D0 (no) 1995-04-12
ZA953052B (en) 1995-10-18
HU9501078D0 (en) 1995-06-28
CY2009006I1 (el) 2010-07-28
DE122009000020I1 (de) 2009-08-06
DE59506707D1 (de) 1999-10-07
CY2011015I2 (el) 2014-04-09
FI118336B (fi) 2007-10-15
HU226860B1 (en) 2009-12-28
ZA953051B (en) 1995-10-18
NO2011020I1 (no) 2011-09-26
CN1266118C (zh) 2006-07-26
LU91373I2 (fr) 2007-12-31
CY2007027I1 (el) 2009-11-04
NO310410B1 (no) 2001-07-02
IL113403A (en) 2001-07-24
TW402582B (en) 2000-08-21
DE122007000071I2 (de) 2009-01-02
LU91564I2 (fr) 2009-07-06
KR100353779B1 (ko) 2003-01-08
NL300296I2 (nl) 2008-02-01
NO951441L (no) 1995-10-19
CZ287935B6 (cs) 2001-03-14
JP3240322B2 (ja) 2001-12-17
NO2009011I1 (no) 2009-06-02
MY119161A (en) 2005-04-30
US5559111A (en) 1996-09-24
CY2007027I2 (el) 2009-11-04
CA2147056C (en) 2005-10-25
DE122007000071I1 (de) 2008-01-31
ES2137478T3 (es) 1999-12-16
US5627182A (en) 1997-05-06
CA2147056A1 (en) 1995-10-19
CN1550491A (zh) 2004-12-01
NZ270936A (en) 1997-06-24
IL113403A0 (en) 1995-07-31
FI951771A (fi) 1995-10-19
NL300296I1 (nl) 2007-12-03
HUT74074A (en) 1996-10-28

Similar Documents

Publication Publication Date Title
IL113403A0 (en) Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides
AR017111A1 (es) Composiciones detergentes para el lavado de ropa con polimeros a base de aminas lineales para proporcionar beneficios en cuanto a aspecto exterior eintegridad a las telas lavadas con las mismas
AU1232388A (en) Process for improving the photochemical stability of dyeings on polyester fibre materials
ES2108520T3 (es) Di(met)acrilatos con grupos carbonato ciclicos.
EP0403062A3 (en) Tickened acidic liquid composition with amine fwa useful as a bleaching agent vehicle
BR9505989A (pt) Processo para preparação de aldeídos
DK0953563T3 (da) Fremgangsmåde til fremstilling af depsipeptidderivater samt hidtil ukendte intermediater derfor
PT90831A (pt) Processo para a preparacao de eteres da 2-amino-7-hidroxitetralina
ATE92479T1 (de) Neue 1,3-oxazine.
PT802193E (pt) Processo para a fabricacao de pirimidinas substituidas

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20150416